{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:35:59Z","timestamp":1791974159004,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>This study introduces and validates the CapnoTip<jats:sup>\u00ae<\/jats:sup>, an impaction-based pressurised intraperitoneal aerosol chemotherapy (PIPAC) nebuliser designed to enhance intraperitoneal drug delivery and achieve greater homogeneity to improve treatment outcomes for peritoneal metastasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>CapnoTip<jats:sup>\u00ae<\/jats:sup> was characterised through physical experiments evaluating aerosol granulometry, spray patterns, and aerosolisation angle. Pharmacological efficacy was assessed by using the ex vivo enhanced inverted bovine urinary bladder (eIBUB) model to measure intraperitoneal cisplatin concentration and distribution homogeneity and compare the result to that of the clinical reference nebuliser, CapnoPen<jats:sup>\u00ae<\/jats:sup>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Aerosol granulometry using distilled water measured 26.1\u202f\u00b5m (confidence interval [CI] 13.6\u201359.6) for CapnoTip<jats:sup>\u00ae<\/jats:sup> and 27.9\u202f\u00b5m (CI 14.8\u201359.4) for CapnoPen<jats:sup>\u00ae<\/jats:sup>. When using 10\u202fcSt silicone oil, droplet sizes were 56.0\u202f\u00b5m (CI 18.4\u2013245.0) for CapnoTip<jats:sup>\u00ae<\/jats:sup> versus 33.8\u202f\u00b5m (CI 14.3\u201366.5) for CapnoPen<jats:sup>\u00ae<\/jats:sup>. The aerosolisation angle was broader with the CapnoTip<jats:sup>\u00ae<\/jats:sup> compared with the CapnoPen<jats:sup>\u00ae<\/jats:sup> (155.3\u00b0 vs. 67.1\u00b0). CapnoTip<jats:sup>\u00ae<\/jats:sup> achieved a uniform intraperitoneal drug distribution, with no significant cisplatin gradient along the aerosolisation axis (<jats:italic>p<\/jats:italic> &gt; 0.05). In contrast, CapnoPen<jats:sup>\u00ae<\/jats:sup> showed marked concentration gradients between the test organ\u2019s top vs. bottom and middle vs. bottom regions (<jats:italic>p<\/jats:italic> &lt; 0.001). A significantly higher mean intraperitoneal cisplatin concentration was achieved with the CapnoTip<jats:sup>\u00ae<\/jats:sup> (56.8\u202f\u00b1\u202f25.1\u202fng\/mg) compared with the CapnoPen<jats:sup>\u00ae<\/jats:sup> (39.2\u202f\u00b1\u202f31.1\u202fng\/mg; <jats:italic>p<\/jats:italic> = 0.026).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The CapnoTip<jats:sup>\u00ae<\/jats:sup> impaction-nozzle nebuliser for PIPAC is technically and pharmacologically equivalent to the CE-approved CapnoPen<jats:sup>\u00ae<\/jats:sup>, while offering superior intraperitoneal drug delivery and distribution homogeneity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-17602-4","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T08:28:23Z","timestamp":1750840103000},"page":"7981-7989","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design and Validation of an Impaction-Nozzle Nebuliser for Enhanced Distribution Uniformity in Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) Applications"],"prefix":"10.1245","volume":"32","author":[{"given":"Yaroslaw","family":"Sautkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Schoenfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Andr\u00e9","family":"Reymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"17602_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041125","author":"A Di Giorgio","year":"2023","unstructured":"Di Giorgio A, Macr\u00ec A, Ferracci F, et al. 10 years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): a systematic review and meta-analysis. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15041125.","journal-title":"Cancers."},{"issue":"7","key":"17602_CR2","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/s1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368\u201377. https:\/\/doi.org\/10.1016\/s1470-2045(19)30318-3.","journal-title":"Lancet Oncol."},{"issue":"1","key":"17602_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/cancers12010034","volume":"12","author":"G Nadiradze","year":"2019","unstructured":"Nadiradze G, Horvath P, Sautkin Y, et al. Overcoming drug resistance by taking advantage of physical principles: pressurized intraperitoneal aerosol chemotherapy (PIPAC). Cancers. 2019;12(1):34. https:\/\/doi.org\/10.3390\/cancers12010034.","journal-title":"Cancers"},{"issue":"2","key":"17602_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","volume":"21","author":"W Solass","year":"2014","unstructured":"Solass W, Kerb R, M\u00fcrdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553\u20139. https:\/\/doi.org\/10.1245\/s10434-013-3213-1.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"17602_CR5","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","volume":"26","author":"W Sola\u00df","year":"2012","unstructured":"Sola\u00df W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26(7):1849\u201355. https:\/\/doi.org\/10.1007\/s00464-012-2148-0.","journal-title":"Surg Endosc."},{"issue":"13","key":"17602_CR6","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1245\/s10434-019-07695-z","volume":"26","author":"U Giger-Pabst","year":"2019","unstructured":"Giger-Pabst U, Bucur P, Roger S, et al. Comparison of tissue and blood concentrations of oxaliplatin administrated by different modalities of intraperitoneal chemotherapy. Ann Surg Oncol. 2019;26(13):4445\u201351. https:\/\/doi.org\/10.1245\/s10434-019-07695-z.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"17602_CR7","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00432-016-2234-0","volume":"142","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Kern AJP, et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol. 2016;142(11):2275\u201380. https:\/\/doi.org\/10.1007\/s00432-016-2234-0.","journal-title":"J Cancer Res Clin Oncol."},{"key":"17602_CR8","doi-asserted-by":"publisher","DOI":"10.1101\/2023.03.24.23287646","author":"D G\u00f6hler","year":"2023","unstructured":"G\u00f6hler D, Oelschl\u00e4gel K, Ouaissi M, Giger-Pabst U. Comparative analysis of nebulizers in clinical use for pressurized intraperitoneal aerosol chemotherapy (PIPAC). medrxiv. 2023. https:\/\/doi.org\/10.1101\/2023.03.24.23287646.","journal-title":"medrxiv."},{"issue":"10","key":"17602_CR9","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1007\/s00464-024-11172-4","volume":"38","author":"Y Sautkin","year":"2024","unstructured":"Sautkin Y, Weinreich J, Reymond MA. A multi-nozzle nebuliser does not improve tissue drug delivery during PIPAC. Surg Endosc. 2024;38(10):5832\u201341. https:\/\/doi.org\/10.1007\/s00464-024-11172-4.","journal-title":"Surg Endosc."},{"key":"17602_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejpb.2021.10.001","volume":"169","author":"H Braet","year":"2021","unstructured":"Braet H, Rahimi-Gorji M, Debbaut C, et al. Exploring high pressure nebulization of Pluronic F127 hydrogels for intraperitoneal drug delivery. Eur J Pharm Biopharm. 2021;169:134\u201343. https:\/\/doi.org\/10.1016\/j.ejpb.2021.10.001.","journal-title":"Eur J Pharm Biopharm."},{"issue":"3","key":"17602_CR11","doi-asserted-by":"publisher","first-page":"20190017","DOI":"10.1515\/pp-2019-0017","volume":"4","author":"I Sautkin","year":"2019","unstructured":"Sautkin I, Solass W, Weinreich FJ, et al. A real-time ex vivo model (eIBUB) for optimizing intraperitoneal drug delivery as an alternative to living animal models. Pleura Perit. 2019;4(3):20190017. https:\/\/doi.org\/10.1515\/pp-2019-0017.","journal-title":"Pleura Perit"},{"issue":"8","key":"17602_CR12","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1007\/s00464-021-08577-w","volume":"35","author":"L Toussaint","year":"2021","unstructured":"Toussaint L, Sautkin Y, Illing B, et al. Correction to: comparison between microcatheter and nebulizer for generating Pressurized IntraPeritoneal aerosol chemotherapy (PIPAC). Surg Endosc. 2021;35(8):4901. https:\/\/doi.org\/10.1007\/s00464-021-08577-w.","journal-title":"Surg Endosc."},{"issue":"10","key":"17602_CR13","doi-asserted-by":"publisher","first-page":"7848","DOI":"10.1007\/s00464-022-09525-y","volume":"36","author":"P H\u00f6ltzcke","year":"2022","unstructured":"H\u00f6ltzcke P, Sautkin I, Clere S, et al. Feasibility of pressurized intra peritoneal aerosol chemotherapy using an ultrasound aerosol generator (usPIPAC). Surg Endosc. 2022;36(10):7848\u201358. https:\/\/doi.org\/10.1007\/s00464-022-09525-y.","journal-title":"Surg Endosc."},{"issue":"2","key":"17602_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1515\/pp-2017-0010","volume":"2","author":"E de Bree","year":"2017","unstructured":"de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Perit. 2017;2(2):47\u201362. https:\/\/doi.org\/10.1515\/pp-2017-0010.","journal-title":"Pleura Perit"},{"issue":"2","key":"17602_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1515\/pp-2017-0004","volume":"2","author":"M Steuperaert","year":"2017","unstructured":"Steuperaert M, Debbaut C, Segers P, Ceelen W. Modelling drug transport during intraperitoneal chemotherapy. Pleura Perit. 2017;2(2):73\u201383. https:\/\/doi.org\/10.1515\/pp-2017-0004.","journal-title":"Pleura Perit"},{"issue":"2","key":"17602_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1515\/pp-2023-0004","volume":"8","author":"AC Ezanno","year":"2023","unstructured":"Ezanno AC, Malgras B, Pocard M. Pressurized intraperitoneal aerosol chemotherapy, reasons for interrupting treatment: a systematic review of the literature. Pleura Perit. 2023;8(2):45\u201353. https:\/\/doi.org\/10.1515\/pp-2023-0004.","journal-title":"Pleura Perit"},{"issue":"1","key":"17602_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/pp-2022-0102","volume":"7","author":"O Sgarbura","year":"2022","unstructured":"Sgarbura O, Eveno C, Alyami M, et al. Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura Perit. 2022;7(1):1\u20137. https:\/\/doi.org\/10.1515\/pp-2022-0102.","journal-title":"Pleura Perit."},{"issue":"1","key":"17602_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.tice.2016.11.004","volume":"49","author":"JO van Baal","year":"2017","unstructured":"van Baal JO, Van de Vijver KK, Nieuwland R, et al. The histophysiology and pathophysiology of the peritoneum. Tissue Cell. 2017;49(1):95\u2013105. https:\/\/doi.org\/10.1016\/j.tice.2016.11.004.","journal-title":"Tissue Cell."},{"issue":"16","key":"17602_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202000655","volume":"9","author":"L Van de Sande","year":"2020","unstructured":"Van de Sande L, Rahimi-Gorji M, Giordano S, et al. Electrostatic intraperitoneal aerosol delivery of nanoparticles: proof of concept and preclinical validation. Adv Healthc Mater. 2020;9(16):e2000655. https:\/\/doi.org\/10.1002\/adhm.202000655.","journal-title":"Adv Healthc Mater."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17602-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17602-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17602-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:06:00Z","timestamp":1758549960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17602-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["17602"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17602-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was funded by CapnoPharm GmbH, T\u00fcbingen, Germany, and performed at the R&D Facility CapnoPharm GmbH, T\u00fcbingen, Germany. The patent DE102022104560A12023.08.31 protects CapnoTip\u00ae and DE102017006185A1 \u2013 CapnoPen\u00ae. MAR, YS, and HS are employees of CapnoPharm GmbH, T\u00fcbingen, Germany. MAR has an equity interest in CapnoPharm GmbH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Diclosure"}}]}}